Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Metabasis Therapeutics has completed patient enrollment in its proof-of-concept Phase IIa clinical trial for MB07803, a product candidate being studied as a treatment for patients with type 2 diabetes.
Subscribe to our email newsletter
With this trial fully enrolled and the final patients undergoing dosing, the company expects to be able to announce top line results in the second quarter of 2008, as planned. The 28-day trial is a randomized, double-blind, placebo-controlled trial involving over 100 patients with type 2 diabetes. Patients received either placebo or MB07803 at an oral dose of 10, 50, 100 or 200mg once daily. The clinical trial is evaluating the change from baseline on day 28 in fasting plasma glucose (FPG).
Mark Erion, executive vice president of research and development and chief scientific officer of Metabasis said: “The results from the soon to be completed Phase IIa clinical trial will provide important safety and glucose-lowering data in patients with type 2 diabetes and could provide further support for the importance of this new approach for the treatment of patients with type 2 diabetes.”